Kyntra Bio, Inc.
LSE: 0IL8.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Thane Wettig
- Employees
- 225
- Headquarters
- San Francisco, United States
- IPO year
- 2018
- Market cap
- $28.4M
- Website
- https://www.kyntrabio.com
Loading 0IL8…
Loading profile data…Frequently asked questions about 0IL8
What does Kyntra Bio, Inc. (0IL8.L) do?
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff...
Where does 0IL8.L trade?
Kyntra Bio, Inc. (0IL8.L) trades on the London Stock Exchange.
What sector is 0IL8.L in?
Kyntra Bio, Inc. (0IL8.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Kyntra Bio, Inc.?
Thane Wettig is the chief executive officer of Kyntra Bio, Inc. (0IL8.L).
Where is Kyntra Bio, Inc. headquartered?
Kyntra Bio, Inc. is headquartered in United States.
Does 0IL8.L pay a dividend?
Kyntra Bio, Inc. (0IL8.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IL8.L go public?
Kyntra Bio, Inc. (0IL8.L) completed its initial public offering in 2018.